VACC vs. SKYE, SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, and LLY
Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 0.7% of Skye Bioscience shares are owned by insiders. Comparatively, 6.0% of Vaccitech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
Vaccitech received 15 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.
In the previous week, Skye Bioscience had 2 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for Skye Bioscience and 0 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.42 beat Skye Bioscience's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.
Skye Bioscience has a net margin of 0.00% compared to Skye Bioscience's net margin of -409.18%. Skye Bioscience's return on equity of -23.41% beat Vaccitech's return on equity.
Vaccitech has higher revenue and earnings than Skye Bioscience.
Skye Bioscience presently has a consensus price target of $22.00, indicating a potential upside of 89.49%. Vaccitech has a consensus price target of $7.63, indicating a potential upside of 299.21%. Given Skye Bioscience's higher possible upside, analysts clearly believe Vaccitech is more favorable than Skye Bioscience.
Summary
Vaccitech beats Skye Bioscience on 8 of the 15 factors compared between the two stocks.
Get Vaccitech News Delivered to You Automatically
Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccitech Competitors List
Related Companies and Tools
